Official Title: “Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost”

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Study Type: Interventional

Study Design: Non-Randomized, Open Label, Active Control, Single Group Assignment

Intervention(s) in this Clinical Trial

• Drug: Bimatoprost 0.03%, Latanoprost

Inclusion Criteria:

• · Male or female > 18 years of age
• Documented low-responder to latanoprost therapy as delineated in the outline above.
• Diagnosis of open-angle glaucoma or ocular hypertension
• Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

• · Known contraindication to bimatoprost or any component of any study medication
• Uncontrolled systemic disease
• Active ocular disease other than glaucoma or ocular hypertension
• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
• History of intraocular surgery within the last 3 months

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Lead Sponsor: Innovative Medical

Overall Clinical Trial Officials and Contacts

Robert Noecker, MD Principal Investigator UPMC Eye Center  

Information obtained from ClinicalTrials.gov on November 19, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00347841

Study ID Number: 5178

ClinicalTrials.gov Identifier: NCT00347841

Health Authority: United States: Institutional Review Board